Cara Therapeutics | CARA - Interest Expense On Debt

Stock Price
3.34
Daily Change
0.18 5.70%
Monthly
-14.14%
Yearly
-81.70%
Q2 Forecast
2.82

Cara Therapeutics reported 39.02M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Assertio Holdings USD 758K 1000 Jun/2024
Cara Therapeutics 39.02M 4.73M Sep/2025
Cassava Sciences USD 129.73M 5.65M Sep/2025
Chugai Pharma JPY 95M 260M Dec/2025
Cipla INR 140.3M 8.5M Dec/2025
Compugen USD 954K 116K Sep/2025
CSL USD 215M 111M Dec/2025
Grifols EUR 156.07M 31.46M Sep/2025
Halozyme Therapeutics USD 4.91M 615K Dec/2025
J&J USD 18M 290M Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pacira USD 3.89M 387K Dec/2025
Pfizer USD 711M 59M Dec/2025
RedHill Biopharma USD 89.8K 31.69M Jun/2024
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Vanda Pharmaceuticals 601.14M 23.61M Sep/2025